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Abstract 
In neuroblastoma (NB), one of the most common paediatric solid tumours, activation 
of anaplastic lymphoma kinase (ALK) is often associated with poor outcomes. Although 
genetic studies have identified copy number alteration and nonsynonymous mutations 
of ALK, the regulatory mechanism of ALK signalling at protein levels is largely elusive. 
Neuronal leucine-rich repeat 1 (NLRR1) is a type 1 transmembrane protein that is 
highly expressed in unfavourable NB and potentially influences receptor tyrosine kinase 
signalling. Here, we showed that NLRR1 and ALK exhibited a mutually exclusive 
expression pattern in primary NB tissues by immunohistochemistry. Moreover, dorsal 
root ganglia of Nlrr1+/+ and Nlrr1-/- mice displayed the opposite expression patterns of 
Nlrr1 and Alk. Of interest, NLRR1 physically interacted with ALK in vitro through its 
extracellular region. Notably, the NLRR1 ectodomain impaired ALK phosphorylation 
and proliferation of ALK-mutated NB cells. A newly identified cleavage of the NLRR1 
ectodomain also supported NLRR1-mediated ALK signal regulation in trans. Thus, we 
conclude that NLRR1 appears to be an extracellular negative regulator of ALK 
signalling in NB and neuronal development. Our findings may be beneficial to 
comprehend NB heterogeneity and to develop a novel therapy against unfavourable NB. 
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Introduction 
Neuroblastoma (NB) is the most common extracranial solid tumour in children with 
heterogeneous clinical outcomes. Tumours diagnosed before 18 months of age with a 
triploid DNA karyotype and low grade of metastasis show favourable outcomes even 
with spontaneous regression, whereas those in older patients with MYCN amplification, 
a diploid DNA karyotype, and frequent metastasis have unfavourable outcomes with a 
less than 50% overall survival rate
1
. Recent genomic studies have revealed novel 
prognostic markers and potential molecular targets in unfavourable NB
2
. However, the 
crucial roles of the gene products in NB, especially their functional interactions 
regulating cell signals, are largely elusive. 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that is highly 
expressed in embryonic nervous tissues and adult brains
3–6
. Although its physiological 
ligands are still controversial in mammals
7–14
, in vivo studies have implied that ALK 
contributes to neurogenesis and learning ability
15–17
. In humans, an aberrant status of 
ALK, such as fusion oncoproteins by chromosomal translocation, nonsynonymous 
mutations within the kinase domain, and overexpression, is associated with 
carcinogenesis and poor prognoses in various cancers
18
. In both familial and 
approximately 6–10% of sporadic NBs, point mutations have been identified in frequent 
sites at F1174 and R1275
19–22
. Among the mutations, F1174L is the most frequent and 
oncogenic, transforming murine fibroblasts and neural crest cells
22,23
, potentiating 
MYCN-driven tumorigenesis in vivo
17,24–26
, and showing resistance to the first clinically 
available ALK inhibitor, crizotinib
27,28
. In addition, gene amplification of ALK, 
accounting for around 3% of NBs, and its aberrantly truncated form result in 
constitutive activation of ALK
22,29–31
. Furthermore, overexpression of ALK at mRNA 
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and protein levels without genomic alterations is associated with unfavourable 
outcomes
32–34
. Therefore, understanding the regulatory mechanism of ALK signalling 
should advance our knowledge concerning the development of NB. 
Neuronal leucine-rich repeat 1 (NLRR1), one of the members of the neuronal 
leucine-rich repeat family encoding type I transmembrane proteins, was previously 
identified as a prognostic factor in high-risk NB
35
. In the gene family, NLRR1 and 
NLRR3 are expressed in unfavourable and favourable NBs, respectively, and the 
expression pattern of NLRR2
35
 is unknown. Our recent studies have revealed that 
NLRR1 is a direct transcriptional target of MYCN, and NLRR1 potentiates epidermal 
growth factor receptor (EGFR) and insulin-like growth factor receptor (IGFR) signals, 
which vice versa initiates MYCN transcription
36,37
. However, it is still unclear how 
NLRR1 influences other RTKs in NB. 
Here, we examined the functional relationship between NLRR1 and ALK, and found 
that NLRR1 suppressed ALK signalling through a direct physical interaction. 
Immunohistochemistry of both human primary NBs and mouse dorsal root ganglia 
(DRGs) revealed a mutually exclusive expression pattern of NLRR1 and ALK in vivo, 
which also suggested an inhibitory effect of NLRR1 on ALK. 
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Results 
1. NLRR1 and ALK show mutually exclusive expression in human NB 
The expression levels of NLRR1 and ALK are associated with unfavourable outcomes 
of NB
32–35
. Hence, we randomly selected six primary tumour samples, which were 
diagnosed as stage 3 or 4, and then immunohistochemically investigated the expression 
patterns of NLRR1 and ALK in the specimens. Sample #1 with high expression of 
NLRR1 was negative for ALK, whereas sample #2 with high expression of ALK 
exhibited low expression of NLRR1 (Figure 1a). Notably, three specimens showed 
intratumoral heterogeneity of NLRR1 and ALK. In samples #3 and #4, NLRR1-rich loci 
were faintly stained for ALK (Figure 1a, upper panels of samples #3 and #4), while 
NLRR1-poor regions displayed higher expression of ALK (Figure 1a, lower panels of 
samples #3 and #4). Of interest, NLRR1-rich/ALK-poor and NLRR1-poor/ALK-rich 
cancer cell clusters were mosaically localised in sample #5 (black and white circles in 
Figure 1a, respectively). Although sample #6 did not show the same pattern, NLRR1 
and ALK were generally expressed in different cancer cells that displayed separated or 
neighboured clusters even in an identical tumour. To confirm the heterogeneous 
expression patterns of NLRR1 and ALK, we stained a commercially available human 
tissue array including 10 NBs. The results are summarised in Table 1. Of the tissue array 
samples, two tumours with high expression of NLRR1 were indistinctly stained for 
ALK (Figure 1b i–iv). Conversely, three tumours with high expression of ALK rarely 
harboured NLRR1 (Figure 1b vii–x), although one section expressed intermediate levels 
of NLRR1 and ALK (Figure 1b v and vi). Therefore, NLRR1 and ALK tended to be 
oppositely expressed among different tumours. To reveal the expressional correlation at 
the mRNA level, we performed qPCR analysis using 87 human NB cDNA samples 
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including all International Neuroblastoma Staging System (INSS) stages with 
MYCN-amplified and non-amplified tumours. Despite the opposite expression pattern of 
NLRR1 and ALK in immunohistochemical analyses, NLRR1 and ALK showed no 
significant correlation (Pearson’s r = 0.035, P = 0.749, Figure 1c and Table 2). 
Furthermore, in risk factor classifications (MYCN status, INSS, age, histology, primary 
tumour site, TrkA expression, and prognosis), the expression level of NLRR1 was not 
associated with that of ALK (Table 2). Because a large tumour sample often included 
both NLRR1-rich/ALK-poor and NLRR1-poor/ALK-rich cancer cells (Figure 1a, 
samples #3, #4, and #5), the opposite expression pattern of NLRR1 and ALK might be 
masked in the homogenised mRNA samples. We further examined the expression 
pattern of NLRR1 and ALK in human NB cell lines SK-N-BE, SK-N-DZ, CHP134, 
SMS-SAN, SH-SY5Y, Kelly, and NB-39-nu. Consequently, in both qPCR and western 
blot analyses, CHP134 and SMS-SAN cells highly expressed NLRR1, but they 
exhibited relatively low expression of ALK (Figure 1d). The expression status might 
result in no phosphorylation of ALK in SMS-SAN cells that harbour the F1174L 
mutation. In contrast, other ALK-mutated cell lines, SH-SY5Y (F1174L), Kelly 
(F1174L), and NB-39-nu (amplified), highly expressed ALK with constitutive activation, 
but they showed low expression of NLRR1 (Figure 1d). The homogenous properties of 
cultured cell lines might result in the opposite expression patterns of NLRR1 and ALK at 
the mRNA level, which were not confirmed in clinical samples, although they exhibited 
no statistical significance. Taken together, NLRR1 and ALK were generally expressed 
in different populations of NB cells and exhibited mutually exclusive expression 
patterns mainly in immunohistochemical analyses. 
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Figure 1. NLRR1 and ALK show mutually exclusive expression in human NB. 
a. Expression patterns of NLRR1 and ALK were often mutually exclusive in 
immunohistochemical analysis. Black and white circles indicate 
NLRR1-rich/ALK-poor and NLRR1-poor/ALK-rich cancer cell clusters, respectively. 
Bars: 100 μm. b. ALK expression was lower in NLRR1-rich human NB tissues whereas 
it was enriched in NLRR1-poor ones. Bars: 50 μm. c. The expression level of NLRR1 
was not correlated with that of ALK in qPCR analysis. The correlation was evaluated by 
Pearson’s test. d. The expression patterns of NLRR1 and ALK tended to be converse 
among human NB cell lines. 
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Table 1. The immunostaining of NLRR1 and ALK in human NB tissue array. 
 
Table 2. The expressional correlation of NLRR1 and ALK in human NB. 
 
 
Sample Primary site NLRR1 ALK
#1 Mediastium high -
#2 Abdominal cavity high low
#3 Pelvic cavity Intermediate Intermediate
#4 Adrenal gland low high
#5 Adrenal gland - high
#6 Adrenal gland - -
#7 Adrenal gland low high
#8 Adrenal gland - -
#9 Nose low -
#10 Nose - -
MYCN
INSS
Age
Histology
Primary site
TrkA
Prognosis
Whole 0.035 0.74987
Amplified -0.064 0.58973
Non-amplified -0.047 0.87214
1, 2, 4S -0.086 0.60139
3, 4 0.021 0.88748
< 18 0.004 0.98043
≥ 18 0.134 0.38744
Favorable 0.070 0.30755
Unfavorable 0.180 0.19026
ND 6
Adrenal 0.147 0.34643
Others -0.064 0.67844
High -0.075 0.62146
Low 0.033 0.84239
ND 2
Alive -0.071 0.58263
Dead 0.012 0.95524
Pearson’s r Pn
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2. NLRR1 and ALK show mutually exclusive expression in murine DRGs 
Next, we hypothesised opposite expression patterns of NLRR1 and ALK during 
neuronal development, because both membrane proteins are expressed in embryonic 
central and peripheral nervous tissues
3–6,38,39
. Using Nlrr1-/- mouse embryos, we 
performed immunohistochemistry of Nlrr1 and Alk, and focused on DRGs that originate 
from neural crest cells, similar to NB. On embryonic day (E) 13.5, Alk was intensely 
stained in Nlrr1-/- DRGs, while the expression level of Alk was low in Nlrr1+/+ DRGs, 
implying that Nlrr1 and Alk were also oppositely expressed during neuronal 
development (Figure 2). 
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Figure 2. NLRR1 and ALK show mutually exclusive expression in murine DRGs 
Nlrr1-expressing cells were enriched in Nlrr1+/+ DRGs, whereas ALK-expressing cells 
occupied DRGs in Nlrr1-/- mice. Bars: 50 μm. 
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3. The extracellular region of NLRR1 physically interacts with ALK 
 The mutually exclusive expression of NLRR1 and ALK in human NB and murine 
DRGs encouraged us to investigate their extracellular interaction. First, we transiently 
expressed NLRR1 tagged with HA (NLRR1-HA or N1-HA) and wild-type (WT) ALK 
in HEK293 cells and then performed immunoprecipitation followed by western blotting. 
The results indicated a physical interaction between these membrane proteins (Figure 3a, 
left panel). NLRR1 also directly bound to oncogenic ALK mutants F1174L and R1275Q 
in the transiently co-expressing cells (Figure 3a, right panel). Treatment of the cells with 
tunicamycin, an N-liked glycosylation inhibitor, showed no influence on the interaction, 
suggesting that NLRR1 physically interacts with ALK regardless of its N-glycosylation 
(Figure 3b). The endogenous interaction between NLRR1 and ALKs was confirmed in 
CHP134 and SMS-SAN cells, both of which endogenously harboured detectable levels 
of NLRR1 and ALK in western blot analyses (Figure 1d and 3c). Next, we transfected 
Cos7 cells with NLRR1-HA or WT ALK independently, and then co-cultured them. In 
the post co-cultured sample, ALK was co-precipitated with NLRR1, suggesting that 
NLRR1 interacts with ALK through its extracellular region among neighbouring cells 
(Figure 3d). To confirm binding of the NLRR1 extracellular domain to ALK, we 
generated an intact extracellular domain of NLRR1 (exN1) fused with human placental 
alkaline phosphatase (AP) at the C-terminal (exN1-AP) using a pSecTag2 template 
vector. Then, Cos7 cells transiently expressing ALK were treated with conditioned 
medium containing the exN1-AP, followed by measurement of AP activities in the 
lysates. Significantly higher AP activity in ALK-expressing cells compared with control 
cells indicated binding of the NLRR1 ectodomain to ALK (Figure 3e). We also 
investigated potential binding of the NLRR1 ectodomain to NLRR1-expressing cells, 
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because LRR domain has been reported to be responsible for protein dimerization
40
. 
However, the AP activity of NLRR1-expressing cells was comparable to that of the 
control (Figure 3e). Additionally, to examine the direct interaction between the NLRR1 
ectodomain and ALK, and to determine the domain of NLRR1 responsible for the 
binding, we newly generated the exN1 and its deletion mutants conjugated with human 
IgG1 Fc at the C-terminus using a pFUSE-hIgG1-Fc2 template vector. Because NLRR1 
has three domains in the extracellular region, LRR, immunoglobulin-like (Ig-like), and 
fibronectin type III (FNIII) domains, the following three chimeric proteins were 
established: the exN1-Fc, ΔLRR-FC encompassing Ig-like and FNIII domains, and 
ΔL-Ig-FC encompassing only the FNIII domain (Figure 3f). Human IgG1 Fc was used 
as a negative control. NB-39-nu cells were treated with conditioned medium containing 
the Fc chimeric proteins, and the lysates were subjected to protein A pull-down. As a 
result, ALK was co-precipitated with all of the Fc-fused mutants, but not with the Fc 
control (Figure 3g), implying that the NLRR1 ectodomain certainly binds to ALK and 
that the FNIII domain is responsible for the physical interaction between NLRR1 and 
ALK. No positive band of IGFR in the protein A pull-down indicated specific binding 
of the NLRR1 ectodomain to ALK (Figure 3g). 
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Figure 3. The extracellular region of NLRR1 physically interacts with ALK. 
a. NLRR1 interacted with WT, F1174L and R1275Q ALKs in co-transfected HEK293 
cells. b. Unglycosylated NLRR1 and ALK exhibited a physical interaction in HEK293 
cells. c. The endogenous interaction between NLRR1 and ALK was confirmed in 
CHP134 and SMS-SAN cells. d. NLRR1 and ALK displayed the physical interaction 
among neighbouring cells. The positive control (P.C.) was a co-transfected sample. e. 
The exN1 bound to ALK-expressing cells. The binding ability was evaluated by AP 
activity. Data are means ± s.d. *P < 0.05. f. The structure of full-length NLRR1 and the 
Fc-chimeric proteins were displayed. g. The exN1 bound to ALK through the FNIII 
domain. The human IgG1 Fc-conjugated proteins and ALK were co-precipitated by 
protein A agarose beads. 
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4. ALK phosphorylation is suppressed by the extracellular region of NLRR1 
Because NLRR1 potentially affects other RTK signals
37
, we examined the ALK 
phosphorylation status in the presence of NLRR1. We transiently expressed NLRR1-HA 
in NB cell lines with constitutively activated ALK signalling and a low level of 
endogenous NLRR1. As the positive control of impaired ALK phosphorylation, 
SH-SY5Y and NB-39-nu cells were treated with 100 nM crizotinib, a kinase inhibitor of 
ALK. Although the treatment completely suppressed phosphorylation of amplified ALK, 
the F1174L mutant was still activated (Figure 4a). This result was consistent with 
previous reports in which the F1174L mutant was resistant to crizotinib
27,28
. Intriguingly, 
in both cell lines, NLRR1 overexpression impaired ALK phosphorylation with no 
obvious alteration of total ALK protein (Figure 4a). In addition, CHP134 and 
SMS-SAN cells were subjected to knockdown of NLRR1. Consistent with the reduced 
ALK phosphorylation upon ectopic NLRR1 expression (Figure 4a), three independent 
shRNAs slightly elevated phosphorylation of ALK (Figure 4b). Our binding assays 
revealed an interaction between the NLRR1 ectodomain and ALK (Figure 3). Hence, 
the negative effect of NLRR1 on ALK phosphorylation was also examined in trans. We 
co-cultured NB cell lines stably expressing enhanced green fluorescent protein (EGFP) 
with MCF7 cells transfected with a control vector or NLRR1-HA (MCF7-ctrl and 
MCF7-NLRR1, respectively), because MCF7 cells had no detectable level of 
endogenous ALK. Although CHP134 cells harboured no phosphorylated ALK, ectopic 
ALK expression in the cells (CHP134-ALK) resulted in detectable level of ALK 
phosphorylation (Figure 4c). Of note, ectopic and endogenous ALK phosphorylation in 
CHP134 and SH-SY5Y cells, respectively, were impaired by co-culture with 
MCF7-NLRR1 cells (Figure 4c). Consistently, ERK phosphorylation was suppressed in 
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CHP134-ALK cells neighbour on MCF7-NLRR1 cells (Figure 4d). Taken together, 
these results suggested that NLRR1 might attenuate ALK phosphorylation in 
neighbouring cells. 
Considering the separation of NLRR1-rich and ALK-rich cancer cell clusters in human 
NB tissue specimens, the intracellular short tail of NLRR1 and the proteolytic cleavage 
of NLRR3 at the transmembrane region
41
, we hypothesised that NLRR1 should also act 
as a soluble form of the extracellular domain after cleavage. To identify the cleaved 
form, N-terminal HA-tagged NLRR1 (HA-N1) was expressed in HEK293 cells, and the 
conditioned medium was subjected to immunoprecipitation against HA. The cleaved 
N-terminal fragment of NLRR1 was observed in western blot analysis when the cells 
were cultured in 10% fetal bovine serum (FBS)-containing medium (Figure 4e). To 
estimate the molecular weight, we yielded the exN1 protein conjugated with a myc/His 
tag using a pSecTag2 construct. Purified by His tag affinity columns (pexN1), the 
pexN1 exhibited almost 90 kDa in western blotting, which was comparable to the 
cleaved N-terminal fragment of NLRR1 (Figure 4e). Thus, the intact NLRR1 
ectodomain was certainly cleaved and secreted into the culture medium. The N-terminal 
fragment was decreased under the serum-free condition, suggesting that soluble factors 
in the serum directly trigger the cleavage or it is affected by cell viability. To test the 
latter hypothesis, we investigated the cleavage of NLRR1 at different confluences of 
SH-SY5Y cells transfected with HA-N1. An immunoprecipitation assay employing the 
conditioned medium showed that shedding of the NLRR1 ectodomain was promoted in 
a higher confluent condition (Figure 4f). Consistent with the enhanced shedding, the 
cells at higher confluency harboured a lower level of full-length HA-N1 in the total cell 
lysates. The band intensity of the NLRR1 ectodomain appeared to increase 
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exponentially against the number of cells (Figure 4f), suggesting that the shedding may 
depend not only on the number of cells but also cell-cell contact. Moreover, 
exN1-containing medium treatment promoted the cleavage (Figure 4f). This result may 
shed a light on the reason why NLRR1-expressing cells displayed the low AP activity 
upon the exN1-AP treatment (Figure 3e). Because the extracellular NLRR1-NLRR1 
interaction might trigger shedding of NLRR1, the exN1-AP treatment possibly 
enhanced the cleavage and release of full-length NLRR1 from the cell surface, thereby 
leading to the low AP activity after washing. Taken together, the extracellular 
interaction of full-length NLRR1 proteins should trigger their own cleavage. 
Furthermore, to examine the presence of the NLRR1 ectodomain in vivo, we performed 
immunoprecipitation analysis employing healthy human plasma samples. As a result, 
the NLRR1 ectodomain was detected in three infant plasma samples, but not in adult 
plasma samples (Figure 4g). Moreover, we developed a sandwich enzyme-linked 
immunosorbent assay (ELISA) system to measure the concentration of the NLRR1 
ectodomain in human plasma. Consistent with the immunoprecipitation, the 
concentration of the NLRR1 ectodomain in healthy infant (<10 years old) plasma was 
significantly much higher than that in adult (>20 years old) samples (median value: 60.8 
μg/ml vs. 17.3 μg/ml, Figure 4h). These data indicated the presence of the soluble 
NLRR1 ectodomain in vivo, especially in children. 
 To further assess the inhibitory effect of the NLRR1 ectodomain on ALK, we treated 
SH-SY5Y cells with conditioned medium of HEK293 cells expressing full-length 
NLRR1. As expected, the medium inhibited ALK phosphorylation in a time-dependent 
manner (Figure 4i). We next treated SH-SY5Y cells with the conditioned medium of 
HEK293 cells including the Fc-chimeric exN1 and its deletion mutants. Consequently, 
- 19 - 
the exN1-Fc impaired the phosphorylation of ALK, whereas the ΔLRR-FC and 
ΔL-Ig-FC had no effect on the signal (Figure 4j). These data suggested the importance 
of the LRR domain or full-length structure of NLRR1 in the inhibitory effect on ALK 
phosphorylation although the FNIII domain was shown to be responsible for the binding 
(Figure 3g). Therefore, the functioning and binding domains of NLRR1 are possibly 
different. Furthermore, the pexN1 treatment impeded the phosphorylation of ALK, AKT, 
and ERK in SH-SY5Y cells (Figure 4k). Therefore, we concluded that the NLRR1 
ectodomain negatively regulated ALK signalling in trans. 
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Figure 4. The extracellular region of NLRR1 suppresses ALK phosphorylation. 
a. Transient expression of NLRR1 suppressed ALK phosphorylation in ALK-mutated 
NB cell lines. b. The knockdown of NLRR1 restored phosphorylation of ALK in 
CHP134 and SMS-SAN cells. c. ALK phosphorylation was impaired by co-culture with 
NLRR1-expressing cells. d. Phosphorylation of ERK in CHP134-EGFP-ALK was 
decreased by neighbouring MCF7-NLRR1 cells. White arrows indicate 
CHP134-EGFP-ALK cells. e. The NLRR1 ectodomain was secreted into the culture 
medium. f. High cellular confluency and the exN1 treatment enhanced the cleavage of 
the NLRR1 ectodomain. g, h. The NLRR1 ectodomain was enriched in human infant 
plasma. The statistical difference between infants and adults was evaluated by the 
Mann–Whitney test. ***P < 0.001. i. Conditioned medium of NLRR1-expressing cells 
repressed ALK phosphorylation. j. The LRR domain was essential for the inhibitory 
effect on ALK phosphorylation. k. The pexN1 treatment attenuated ALK 
phosphorylation. 
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5. NLRR1 impairs ALK-expressing cell expansion 
Considering the negative effect of the NLRR1 ectodomain on ALK signalling, we 
hypothesised that the proliferation of ALK-mutated NB cells might be suppressed by 
the NLRR1 ectodomain. In the co-culture assay performed in Figure 4c, the increase of 
total EGFP intensity in CHP134-ALK and SH-SY5Y cells was significantly diminished 
by the neighbouring MCF7-NLRR1 cells (Figure 5a). The live MCF7-NLRR1 cells 
possibly occupied a larger area than the control cells, resulting in suppression of NB cell 
growth in the co-culture condition. Hence, we next fixed MCF7-NLRR1 cells on the 
surface of the culture plate and then incubated SH-SY5Y and NB-39-nu cells in the 
wells. Consequently, the cell proliferation was remarkably attenuated by culture on the 
fixed NLRR1-expressing cell layer compared with that on the fixed control cells (Figure 
5b). To evaluate the inhibitory effect on cell growth by the exN1 molecule, the 
Fc-chimeric exN1 and its deletion mutants were introduced into 96-well plates coated 
with protein G. Then, SH-SY5Y and NB-39-nu cells were cultured in these plates. Of 
the chimeric proteins, the fixed exN1-Fc suppressed cell proliferation, whereas the other 
two deletion mutants exhibited marginal effects (Figure 5c). This result also suggested 
that the negative effect of NLRR1 on ALK required the LRR domain. Furthermore, the 
pexN1 treatment decreased the growth of SH-SY5Y cells compared with untreated and 
vehicle-treated controls (Figure 5d). Therefore, the NLRR1 ectodomain certainly 
suppressed ALK-mutated NB cell proliferation. 
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Figure 5. NLRR1 impairs ALK-expressing cell expansion. 
a. ALK-expressing NB cell expansion was repressed by co-culture with 
NLRR1-expressing cells. Cell expansion for 5 days was evaluated as the increase of 
EGFP intensity. Data are means ± s.d. b. ALK-mutated NB cell growth was inhibited by 
a fixed layer of NLRR1-expressing cells. d. The exN1 abrogated ALK-mutated NB cell 
proliferation and the LRR domain was required for the effect. d. The pexN1 treatment 
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reduced impaired SH-SY5Y cell growth. Through flow of the mock cell conditioned 
medium in His tag affinity purification was utilized for the control in the right graph. 
Data are means ± s.d. *P < 0.05, **P < 0.01, and ***P < 0.001 
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Discussion 
Here, we provide the first evidence that NLRR1 and ALK exhibit mutually exclusive 
expression patterns in NB tissues and murine DRGs, and that NLRR1 binds to ALK 
through its extracellular region to impair ALK functions in cell proliferation. Several 
ligands have been reported to activate EGFR signalling
42
, whereas an extracellular 
antagonist against human EGFR has been identified recently
43
. These reports imply the 
complexity of ALK signal regulation by potential ALK ligands
7,8,12–14
 and unknown 
extracellular antagonists. Our present data strongly suggest that NLRR1 appears to be 
the first extracellular antagonist against ALK signalling, although this finding needs to 
be further confirmed. 
The functioning and binding domains of NLRR1 are possibly different, because the 
FNIII domain alone was co-precipitated with ALK (Figure 3g), whereas depletion of the 
LRR domain lacked the inhibitory effect on ALK phosphorylation (Figure 4j). 
According to a previous report, the LRR domain is responsible for protein dimerization 
and ligand-receptor interaction
40
. In addition, our data suggested that dimerization of 
NLRR1 triggers shedding of the NLRR1 ectodomain (Figure 4f), and the cleaved 
ectodomain suppressed ALK phosphorylation (Figure 4i, j and k). Hence, we 
hypothesised that LRR domain-mediated dimerization of NLRR1 might have an 
important role in the release of the ectodomain and abrogation of ALK functions. 
We previously reported that MYCN transcriptionally targets NLRR1
36
 to enhance NB 
cell growth, and that NLRR1, vice versa, positively regulates MYCN via EGFR signal 
enhancement
37
. Conversely, MYCN also transactivates ALK
44
, and ALK signalling 
promotes MYCN transcription through activation of ERK5
45
. Thus, both NLRR1 and 
ALK form positive feedback loops with MYCN. However, these MYCN-associated 
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regulatory mechanisms do not exist simultaneously in a single cell under physiological 
conditions. That is because NLRR1 and ALK were independently expressed in 
separated cell clusters of an identical human NB biopsy (Figure 1a), and the NLRR1 
ectodomain had a negative effect on ALK. Therefore, we believe that NLRR1-mediated 
regulation occurs in neighbouring or separated NB cells, which controls the 
ALK-expressing cell population and in part contributes to the mutually exclusive 
expression of NLRR1 and ALK. Specifically, ALK-rich cells may not expand into 
NLRR1-rich cell clusters, but they proliferate well in an NLRR1-poor environment. 
Accordingly, NLRR1 is a direct negative regulator of ALK in trans, but an indirect 
positive regulator of EGFR in cis, although both ALK and EGFR signals enhance cell 
survival and proliferation. 
The physiological and pathological roles of ALK signal regulation by NLRR1 during 
neuronal development and carcinogenesis remain unclear. We found that some cancer 
cells were double-positive for both proteins (sample #6 in Figure 1a and sample #3 in 
Figure 1b). Currently, the biological and clinical significance of double-positive, 
NLRR1-rich/ALK-poor, and NLRR1-poor/ALK-rich cancer cells remain to be 
uncovered. However, intratumoral heterogeneity is one of the crucial problems 
encountered when treating patients with cancer including high-risk NB. Our observation 
of the mutually exclusive expression of NLRR1 and ALK in normal and cancerous 
tissues might provide some important insights into the gene regulation of heterogeneous 
patterning within these tissues. Thus, targeted therapy against both NLRR1 and ALK 
might be possible to treat patients with particular cancers such as high-risk NB. 
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Material & Methods 
Immunohistochemistry of NB tissues. The six NB specimens were surgically 
collected and embedded in paraffin at Kyushu University Hospital. The appropriate 
informed consent was obtained under the institutional review board-approved protocol. 
The formalin-fixed, paraffin-embedded specimens and a purchased tissue array MC803a 
(U.S. Biomax) were deparaffinised and stained with an anti-hNLRR1 antibody (R&D, 
1:250) overnight. The signal was detected by a biotin-conjugated secondary antibody 
and streptavidin-horseradish peroxidase (HRP) (VECTOR), followed by 
diaminobenzidine staining (VECTOR). An ALK detection kit (Nichirei) was used 
according to the manufacturer’s protocol. The study was approved by the Kyushu 
University of Medical Human Investigation Committee and the internal review board of 
the Chiba Cancer Center. The study was performed in accordance with the approved 
guideline. 
Real-time qPCR. Total RNA was extracted by the acid guanidinium 
thiocyanate-phenol-chloroform method from clinical NB samples kindly donated by 
various institutions and hospitals in Japan to the Chiba Cancer Center Neuroblastoma 
Tissue Bank. Reverse transcription was performed with SuperScript II reverse 
transcriptase (Invitrogen). qPCR was carried out using the 7500 Real-Time PCR System 
(Applied Biosystems) according to the manufacturer’s protocol. We employed TaqMan 
probes for NLRR1 (Assay ID: Hs00979743_m1) and ALK (Assay ID: Hs00608292_m1). 
The gene expression was standardised to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA levels. This study procedure was approved by the internal review 
board of Chiba Cancer Center and appropriate informed consent was obtained from 
each institution or hospital. The study was demonstrated in accordance with approved 
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guidelines. To quantify NLRR1 and ALK expression in NB cell lines, total RNA was 
extracted by Trizol from the indicated cell lines according to the manufacture’s protocol. 
Reverse transcription was performed with SuperScript II reverse transcriptase, and the 
PCR was performed in the 7500 Real-Time PCR System using SYBR Premix Ex Taq 
(Takara). The specific primer sequences were: NLRR1, 
5′-GCAGCTTTTCAACTTGACTGAA-3′ and 5′-TGAAGGTTGCTGAGGTCTTGT-3′; 
ALK, 5′-CACTCCAGGGAAGCATGG-3′ and 5′-CACTCGAAATGGGTTGTCTG-3′; 
GAPDH, 5′- ACCTGACCTGCCGTCTAGAA-3′ and 
5′-TCCACCACCCTGTTGCTGTA-3′. 
Immunohistochemistry of mouse embryos. Nlrr1+/+ and -/- mouse embryos at E13.5 
were fixed with 4% paraformaldehyde in PBS at 4°C and frozen in O.T.C. compound 
(Sakura). Transverse sections were incubated with anti-mNlrr1 (raised against the 
C-terminal of mouse Nlrr1, 1:1,000) and anti-ALK (DAKO, 1:50) antibodies overnight 
at 4°C. A M.O.M. Immunodetection Kit (VECTOR) was used to stain with antibodies 
raised in mice. The primary antibodies were labelled by secondary anti-rabbit IgG Alexa 
488 (Molecular Probes, 1:500) and biotinylated anti-mouse IgG (1:250), followed by 
avidin Cy3 (1:1,000). The mouse experiments were approved by the Committee for 
Animal Care at the Chiba Cancer Center Research Institute and carried out in 
accordance with approved guidelines and regulations. 
Cell culture and transfection. NB cell lines (SK-N-BE, SK-N-DZ, CHP134, 
SMA-SAN, SH-SY5Y, Kelly, and NB-39-nu) and non-NB cell lines (HEK293, MCF7, 
and Cos7) were cultured in RPMI-1640 or Dulbecco’s modified Eagle’s medium 
(Sigma) supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco). Cells 
were transfected using FuGENE HD (Promega) or Lipofectamine 3000 (Life 
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technologies) according to the manufacturers’ instructions. EGFP-expressing stable 
clones were selected and maintained in medium containing 400 μg/ml G418 (Sigma). 
Plasmids. Human NLRR1 (NM_020873) tagged with HA at the C-terminal was cloned 
into the BamHI/NotI site of pcDNA3.1-myc-His (Invitrogen). This construct was used 
to generate other NLRR1-related plasmids. For secretion of the intact NLRR1 
ectodomain, the corresponding PCR-amplified fragment of the intact extracellular 
region (exN1: M1-L632) was inserted into the BamHI/XhoI site of the pSecTag2B 
vector (Invitrogen). To fuse the exN1 with human placental alkaline phosphatase (AP: 
NM_001632), the PCR fragment of AP (I18-G489) were inserted into the C-terminal of 
the pSecTag2B-exN1 vector using the In-Fusion cloning technique (Clontech). To 
generate the Fc chimeric proteins, the intact exN1 and its deletion mutants (exN1-Fc: 
M1-L632; ΔLRR-Fc: N362-L632; ΔL-Ig-Fc: V516-L632) were introduced into the 
EcoRI site of pFUSE-hIgG1-Fc2 (Invivogen). The pEGFP-N1 plasmid was employed 
for EGFP-expressing cells. Expression vectors for WT ALK and ALK F1174L were 
kind gifts from Dr. Junko Takita (The University of Tokyo, Tokyo, Japan). The ALK 
R1275Q construct was generated using site-directed mutagenesis. Mission short hairpin 
RNA constructs, NM_020873.3-427s1c1, NM_020873.3-846s1c1, and 
NM_020873.3-1359s1c1, were purchased from Sigma. 
Immunoprecipitation. All procedures were performed at 4°C. Cells were lysed in 
CHAPS lysis buffer [50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, 10 mM CHAPS, and 1 × Protease Inhibitor cocktail (Roche)]. The lysates (500–
2,000 μg protein) and 10 ml conditioned medium were precleared with 20 μl protein A 
agarose bead (Invitrogen) 50% slurry in 500 μl IP buffer (50 mM Tris-HCl, pH 7.4, 150 
mM NaCl, 1% Nonidet P-40, and 1 × Protease Inhibitor cocktail) for 30 minutes. The 
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precleared samples were then incubated with anti-HA tag (Roche), anti-ALK (Cell 
Signaling Technology), and anti-NLRR1 (prepared in-house or purchased from R&D 
Systems) antibodies for 1 hour, followed by addition of 20 μl protein A agarose bead 
50% slurry. Normal rabbit IgG (Santa Cruz Biotechnology) was employed for the 
IP buffer (rotated for 10 minutes twice and inverted four times) and then subjected to 
western blotting. 
Western blotting. The lysates (25–100 μg protein) in CHAPS or RIPA buffer (20 mM 
Tris-HCl, pH 7.6, 140 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
SDS, and 1× Phosphatase Inhibitor cocktail) and precipitated protein A agarose beads 
were boiled in sample buffer for 5 minutes and applied to polyacrylamide gels. After 
separation and transfer, the membranes were reacted with primary antibodies overnight 
at 4°C. The primary antibodies were anti-pALK Y1586 and 1604, anti-pAKT, anti-AKT, 
anti-pERK, anti-ERK, anti-myc tag (Cell Signaling Technology), anti-ALK (Beckman), 
anti-NLRR1 (prepared in-house), anti-HA (Roche), and anti-hIgG1Fc (Millipore) 
diluted at 1:1000 in TBST. After incubation with HRP-conjugated secondary antibodies 
(Santa Cruz Biotechnology, 1:5,000), the protein bands were fluoresced by a 
chemiluminescent substrate (Thermo Scientific). 
Binding assays. Transfected Cos7 cells were incubated for 1 hour at room temperature 
in ultrafiltrated medium from HEK293 cells transfected with the exN1-AP construct. 
After washing and lysis, AP activities in the lysates were measured by Lab Assay ALP 
(Wako) according to the manufacturer’s instructions. The results were standardised to 
the control. For the pull-down with protein A, NB-39-nu cells were incubated in 
conditioned medium containing Fc chimeras from HEK293 cells for 1 hour at 37°C. 
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The washed samples were lysed in CHAPS buffer and 1 mg of sample was directly 
reacted with 30 μl protein A agarose bead 50% slurry in IP buffer overnight at 4°C. The 
samples were washed and then subjected to western blotting. 
Treatments. To reveal the interaction between NLRR1 and ALK under unglycosylated 
conditions, HEK293 cells were treated with 5 μg/ml tunicamycin for 8 hours and then 
subjected to immunoprecipitation. Crizotinib (100 nM) was added to the culture media 
of SH-SY5Y and NB-39-nu cells for 24 hours as the positive control to suppress 
phosphorylation of ALK. To induce the negative effect of the NLRR1 ectodomain on 
ALK phosphorylation, SH-SY5Y cells were exposed to the conditioned medium of 
HEK293 cells transfected with NLRR1-HA or pFUSE constructs, and 10 μg/ml of the 
pexN1. A His-tagged protein purification kit (MBL) was employed to generate the 
pexN1. 
Co-culture assay. For the immunoprecipitation, Cos7 cells transfected with either 
NLRR1-HA or ALK were co-cultured at the same density for 24 hours and then 
subjected to immunoprecipitation with a 3,3′-dithiobis(sulfosuccinimidyl propionate) 
cross-linking reaction. Established EGFP-expressing stable NB cell lines CHP134-ALK 
and SH-SY5Y were combined with MCF7-ctrl or MCF7-NLRR1 cells at 1 × 10
4
 cells 
per cell line in 24-well plates. Co-cultured samples were also subjected to western blot 
analysis and fixed with 4% paraformaldehyde, followed by staining with the anti-pERK 
antibody. 
Detection of the exN1 in vivo. Human plasma samples (5 μl) were mixed with 500 μl 
IP buffer, and the mixtures were pre-cleaned with protein G sepharose beads. The exN1 
was precipitated with 1 μl sheep anti-hNLRR1 antibody (R&D) and then detected by 
mixed mouse anti-hNLRR1 antibodies (both antibodies were raised against the 
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N-terminal of human NLRR1, 1:1,000) with a HRP-conjugated secondary antibody. In 
sandwich ELISA analysis, human plasma samples were captured by the sheep 
anti-hNLRR1 antibody. The mouse anti-hNLRR1 antibody mixture was used for 
detection. 
Cell growth assay. To evaluate the effect of the NLRR1 ectodomain on ALK-mutated 
NB cells, MCF7 cells transfected with NLRR1-HA were seeded in a 96-well plate and 
grown to 70–80% confluence for 24 hours. The cells were then fixed with −20°C 
methanol for 15 minutes. For the cell growth assay on Fc chimeric proteins, protein 
G-coated 96-well plates were incubated with conditioned medium from HEK293 cells 
transfected with pFUSE constructs for 1 hour at room temperature. SH-SY5Y and 
NB-39-nu cells were seeded into the modified plates at 1 × 10
3
 cells per well. SH-SY5Y 
cells seeded into a normal 96-well plate were also treated with 10 μg/ml of the pexN1. 
Cell growth was measured by Cell Counting kit-8 (Dojindo) and a live cell imaging 
system, Incucyte. The quantified growth was standardised to that on day 0. 
Statistics. The correlation between the expression of NLRR1 and ALK in real-time 
qPCR analysis was examined by Pearson’s test. The median concentrations of the 
NLRR1 ectodomain in human infant and adult plasma samples were compared by the 
Mann-Whitney test. Significance in cell growth analyses was evaluated by the Student’s 
t-test after analysis of variance. The binding assay was tested by the Student’s t-test 
only. 
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